Showing 301-310 of 792 results for "".
Get Ready: The Biosimilars Are Here
https://practicaldermatology.com/topics/psoriasis/get-ready-the-biosimilars-are-here/20662/Recent developments mean that biosimilars are finally hitting the US market.Wise Investing
https://practicaldermatology.com/topics/practice-management/wise-investing/20666/The key to building wealth during today's bull markets, bear markets, and corrections.Starting a Practice: Choosing Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/starting-a-practice-choosing-devices/18900/In his new series for Modern Aesthetics® Magazine, Christopher Khorsandi, MD offers tips for aesthetic physicians opening or expanding a practice. In this edition he discusses device selection and integration with an emphasis on marketing and patient conversion.How to Integrate Physician-Dispensed Products
https://practicaldermatology.com/topics/general-topics/PD0609_10-php/22819/With the correct protocols, staff training, and product selection, physician dispensing can help retain your current patient base and assist in marketing to new patients.Internal and External Healing: The Rise of After-Sun Care
https://practicaldermatology.com/topics/skin-cancer-photoprotection/internal-and-external-healing-the-rise-of-after-sun-care/27165/Internal and External Healing: The Rise of After-Sun CareDermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhofade-approved-sun-leaves-acne-behind-radiesse-turns-10/18552/The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking upTaltz Approved, Venus Versa Cleared, Sunbathing Linked to Longevity
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-taltz-approved-venus-versa-cleared-sunbathing-linked-to-longevity/18788/The IL-17 inhibitor Taltz (ixekizumab) from Eli Lilly is approved for adults with plaque psoriasis. Venus Concepts' Venus Versa is cleared for multiple aesthetic indications. Strata Sciences gets FDA clearance for new "Classifier Code" for use with MelaFind. Vitals.com shows that wait times are goinJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database